



CONTACT: Trish Cetrone
925-787-4283
tcetrone@chasepr.com
Chase Communications

Mike Ford
707-256-2403
mford@santeninc.com
Santen Inc.

SANTEN EXPANDS BUSINESS DEVELOPMENT OPERATIONS New Southern California Office Opens in August

NAPA, Calif. (August 10, 2009) – Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) announced the establishment of a satellite office in Irvine, California which will be the base of operations for the business development staff of Santen Inc.

“We are focused on the acquisition of innovative compounds and products in three key areas: retina, glaucoma and dry eye,” says Santen Inc. President and Chief Executive Officer Adrienne Graves, PhD. “The Irvine location will facilitate the Business Development interactions necessary for building a robust global pipeline, particularly for increasing our presence in the U.S. market.”

Santen Inc. continues to aggressively expand its clinical and business development efforts to support the company’s international expansion. Currently, Santen Inc. has four innovative compounds in U.S. clinical development for the glaucoma and corneal disorder therapeutic categories. During the past year, Santen has entered into partnership agreements with MacuSight, Bausch and Lomb and Merck.

“Locating the business development team in this major regional cluster of ophthalmic companies and specialized venture funds allows participation in a well developed network, increasing access to opportunities in support of Santen’s global strategic focus,” says Schalou Newton, EDM, Santen’s Vice President of Strategic Marketing & Business Development.

Santen has four FDA-approved drugs currently marketed in the U.S. Since late 2003, Vistakon Pharmaceuticals has had sole U.S. distribution rights for these products: IQUIX[®] (levofloxacin ophthalmic solution) 1.5%, QUIXIN[®] (levofloxacin ophthalmic solution) 0.5%, BETIMOL[®] (timolol ophthalmic solution) 0.25%, 0.5% and ALAMAST[®] (pemirolast potassium ophthalmic solution) 0.1%. Santen continues to have responsibility for manufacturing, clinical and regulatory activities associated with all four of these products.

-more-

Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a billion-dollar global company headquartered in Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese and Chinese markets and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its wholly-owned Napa, California-based Santen Inc. Santen's global product pipeline includes many more prescription pharmaceuticals in varying clinical trial phases. A detailed listing, as well as additional corporate information, is available online at www.santeninc.com.

#-#-#